Nervous System Diseases

All Conditions

Neoplasms

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Rare Diseases

Migraine Disorders

Ganglion Cysts

Headache

Synovial Cyst

Cysts

Mucinoses

Connective Tissue Diseases

Acute Graft Versus Host Disease

Central Nervous System Depressants

All Drugs and Chemicals

Bupivacaine

Anesthetics

Anesthetics, Local

High dose (3ml) with unilateral administration of bupivacaine

High dose (3ml) with bilateral administration of bupivacaine

Low dose (1ml) with unilateral administration of bupivacaine

Low dose (1ml) with bilateral administration of bupivacaine

Topically applied to sphenopalatine ganglion

Introduced into nose to reach sphenopalatine ganglion nerve

angiocatheter

Benjamin Friedman, MD

Dane McCarthy, PA

The goal of this clinical trial is to compare the administration and dosage of bupivacaine for sphenopalatine ganglion (SPG) nerve block. The main question\[s\] it aims to answer are:

* Does a high dose (3ml) give more relief than a low dose (1ml)?
* Does bilateral administration give more relief than unilateral? Participants with headaches will be asked to lie down and have SPG block performed.

Researchers will compare dosage and administration to see how symptoms are reduced.

Sphenopalatine Ganglion Block Study

A Randomized Trial of a Sphenopalatine Ganglion Block With Bupivacaine for Acute Headache

Pain will be assessed using an 11-point numerical rating scale (NRS) as recommended for use in migraine research by the International Headache Society. The NRS scale asks subjects to assign their pain a number between 0 and 10, with 0 = no pain and 10 = worst pain imaginable. Pain scores will be ascertained prior to procedure and at one hour

A standard ordinal headache intensity scale will be used for participants to describe their headache as either "severe", "moderate", "mild", or "none". The number of participants who are able to achieve a headache level of "mild" or "none" in the ED within 30 minutes of procedure/medication administration and without requiring additional analgesic medication, and not relapsing to a headache level worse than "mild" during the 48 hours after medication administration, will be determined

Satisfaction with the procedure/medication as evidenced by the number of participants who provide an affirmative response to the question "Do you want to receive the same procedure/medication the next time you come to the ER with migraine?"

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Sphenopalatine Ganglion Block Study	NCT05707754	Sphenopalatine ...	Bupivacaine angiocatheter	18 Years -	Montefiore Medical Center
Sphenopalatine Ganglion Block Study	NCT05707754	Sphenopalatine ...	Bupivacaine angiocatheter	18 Years -	Montefiore Medical Center

Spots Global Cancer Trial Database for sphenopalatine ganglion nerve